XTX Topco Ltd Buys Shares of 55,488 Revolution Medicines, Inc. (NASDAQ:RVMD)

Key Points

• XTX Topco Ltd has acquired 55,488 shares of Revolution Medicines, valued at approximately $1,962,000, as per their recent Form 13F filing.
• Analysts have a consensus rating of "Buy" for Revolution Medicines, with price targets ranging from $57.00 to $80.00, signaling strong future expectations.
• Revolution Medicines reported a loss of ($1.13) EPS in its last earnings release, slightly missing expectations and showing year-over-year deterioration.

XTX Topco Ltd purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 55,488 shares of the company's stock, valued at approximately $1,962,000.

Several other large investors also recently modified their holdings of RVMD. Farallon Capital Management LLC boosted its position in shares of Revolution Medicines by 17.1% during the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after buying an additional 1,931,000 shares during the period. Janus Henderson Group PLC boosted its position in shares of Revolution Medicines by 54.5% during the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock worth $414,777,000 after buying an additional 3,346,755 shares during the period. Baker BROS. Advisors LP boosted its position in shares of Revolution Medicines by 4.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock worth $347,163,000 after buying an additional 367,882 shares during the period. Nextech Invest Ltd. boosted its position in shares of Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after buying an additional 1,304,347 shares during the period. Finally, FMR LLC raised its holdings in Revolution Medicines by 14.7% during the fourth quarter. FMR LLC now owns 6,742,083 shares of the company's stock worth $294,899,000 after acquiring an additional 866,190 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $72.00 target price (down previously from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Guggenheim reiterated a "buy" rating and set a $80.00 target price on shares of Revolution Medicines in a report on Wednesday, June 25th. Needham & Company LLC reiterated a "buy" rating and set a $57.00 target price on shares of Revolution Medicines in a report on Tuesday, June 24th. Oppenheimer upped their target price on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, The Goldman Sachs Group initiated coverage on Revolution Medicines in a research note on Tuesday, July 15th. They issued a "buy" rating and a $65.00 price objective on the stock. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat, Revolution Medicines presently has an average rating of "Buy" and a consensus target price of $68.91.

Revolution Medicines Stock Down 1.7%

Shares of Revolution Medicines stock traded down $0.64 on Friday, hitting $36.63. The stock had a trading volume of 978,549 shares, compared to its average volume of 1,474,059. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The business's 50 day moving average is $38.64 and its two-hundred day moving average is $38.89. The stock has a market cap of $6.82 billion, a price-to-earnings ratio of -9.16 and a beta of 1.16.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period last year, the business earned ($0.70) earnings per share. As a group, equities analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.